Cemiplimab Deemed Active, Safe After HHIs in Locally Advanced Basal Cell Carcinoma
Phase 2 trial results supported the approval of cemiplimab for this patient group.
Skin Cancer
Bempegaldesleukin Plus Nivolumab Elicits Responses in Treatment-Naïve, Advanced Melanoma
More than half of patients responded, and responses deepened over time.
Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
Two Doses of COVID-19 Vaccine Appear Necessary to Protect Cancer Patients on Active Treatment
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
Keytruda Approved for Locally Advanced Cutaneous Squamous Cell Carcinoma
Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response.
Melanoma Brain Metastases: ‘Absolutely Treatable in 2021’
Experts outline treatment options and make recommendations.
Study Supports Routine PET-CT Surveillance for Asymptomatic, High-Risk Melanoma
PET-CT results led to management changes in 15% of patients.
LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab
In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Neoadjuvant Nivolumab Plus Relatlimab Produced a High pCR Rate in Stage III-IV Melanoma
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Greater Benefit With Pembrolizumab in Crossover vs Rechallenged Patients With Cutaneous Melanoma
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
- Loading...
Loading...
Loading... 
Loading...